Hypercholesterolemia - Pipeline Review, H2 2014

Date: September 30, 2014
Pages: 153
Price:
US$ 2,000.00 US$ 1,800.00
Offer valid until December 31, 2014!
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: H807BC988B3EN
Leaflet:

Download PDF Leaflet

Summary

Global Markets Direct’s, ‘Hypercholesterolemia - Pipeline Review, H2 2014’, provides an overview of the Hypercholesterolemia’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Hypercholesterolemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hypercholesterolemia and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope
  • The report provides a snapshot of the global therapeutic landscape of Hypercholesterolemia
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Hypercholesterolemia and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Hypercholesterolemia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Hypercholesterolemia pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
Reasons to buy
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Hypercholesterolemia
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Hypercholesterolemia pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Introduction
Global Markets Direct Report Coverage
Hypercholesterolemia Overview
Therapeutics Development
Pipeline Products for Hypercholesterolemia - Overview
Pipeline Products for Hypercholesterolemia - Comparative Analysis
Hypercholesterolemia - Therapeutics under Development by Companies
Hypercholesterolemia - Therapeutics under Investigation by Universities/Institutes
Hypercholesterolemia - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Hypercholesterolemia - Products under Development by Companies
Hypercholesterolemia - Products under Investigation by Universities/Institutes
Hypercholesterolemia - Companies Involved in Therapeutics Development
Bristol-Myers Squibb Company
Johnson & Johnson
Amgen Inc.
Eli Lilly and Company
Merck & Co., Inc.
Pfizer Inc.
Santaris Pharma A/S
SoluBest Ltd.
Alnylam Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
CrystalGenomics, Inc.
Catabasis Pharmaceuticals, Inc.
Planet Biotechnology Inc.
Zhejiang Hisun Pharmaceutical Co., Ltd.
Esperion Therapeutics, Inc.
Progenra, Inc.
Serometrix, LLC
Hanmi Pharmaceuticals, Co. Ltd.
AtheroNova Inc.
Immune Response BioPharma, Inc.
Agilvax, Inc.
Michigan Life Therapeutics, LLC
LondonPharma Ltd
Dybly AG
Hypercholesterolemia - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
anacetrapib - Drug Profile
Product Description
Mechanism of Action
R&D Progress
alirocumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
(aspirin + lisinopril + lovastatin) - Drug Profile
Product Description
Mechanism of Action
R&D Progress
HCP-1306 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ETC-1002 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecule to Inhibit LDL-C for Hypercholesterolemia - Drug Profile
Product Description
Mechanism of Action
R&D Progress
evolocumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
bococizumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
LY-3015014 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
HS-25 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CAT-2003 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AEM-28 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MGL-3196 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ALN-PCS02 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
BMS-962476 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AHRO-001 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
simvastatin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
fluvastatin sodium - Drug Profile
Product Description
Mechanism of Action
R&D Progress
pravastatin sodium - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PF-06678552 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
fenofibrate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ALN-PCSsc - Drug Profile
Product Description
Mechanism of Action
R&D Progress
1D05-FAB - DRUG PROFILE
Product Description
Mechanism of Action
R&D Progress
IR-1002 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
gemcabene calcium - Drug Profile
Product Description
Mechanism of Action
R&D Progress
aplexone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
DYB-186 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecule to Inhibit Endothelial Lipase for Hypercholesterolemia - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Antisense Oligonucleotide to Target miR-33 for Cardiovascular Diseases - Drug Profile
Product Description
Mechanism of Action
R&D Progress
EP-80317 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Vaccine for Metabolic Disorders - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecules for Ophthalmology, Cardiovascular, CNS and Metabolic Disorders - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Synthetic Peptide for Hypercholesterolemia - Drug Profile
Product Description
Mechanism of Action
R&D Progress
SX-PCK9 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecules to Inhibit IDOL for Hypercholesterolemia - Drug Profile
Product Description
Mechanism of Action
R&D Progress
EGF-AB Fc Variants to Inhibit PCSK9 for Hypercholesterolemia - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Drugs to Inhibit Sortilin for Hypercholesterolemia - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecules to Inhibit PCSK9 for Hypercholesterolemia - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Drugs for Hypercholesterolemia - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecule to Inhibit PCSK9 for Hypercholesterolemia - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecule to Inhibit PCSK9 for Hypercholesterolemia - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Hypercholesterolemia - Recent Pipeline Updates
Hypercholesterolemia - Dormant Projects
Hypercholesterolemia - Discontinued Products
Hypercholesterolemia - Product Development Milestones
Featured News & Press Releases
Sep 02, 2014: Amgen Submits Marketing Authorization Application For Novel Investigational LDL Cholesterol-Lowering Medication Evolocumab To The European Medicines Agency
Aug 31, 2014: Regeneron and Sanofi Announce Presentation of Detailed Positive Results from Four Pivotal Alirocumab Trials at ESC Congress 2014
Aug 28, 2014: Amgen Announces Positive Top-Line Results From Phase 3 YUKAWA-2 Trial Of Evolocumab In Combination With Statins In Japanese Patients With High Cardiovascular Risk And High Cholesterol
Aug 28, 2014: Amgen Submits Biologics License Application For Novel Investigational LDL Cholesterol-Lowering Medication Evolocumab To The FDA
Aug 25, 2014: Regeneron and Sanofi to Present Results from Four Phase 3 Alirocumab Trials in Hot Line Session at ESC Congress 2014
Aug 12, 2014: Esperion Therapeutics Provides ETC-1002 Development Program Update
Jul 30, 2014: Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission
Jul 30, 2014: Sanofi and Regeneron Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia
Jul 24, 2014: Esperion Therapeutics Announces Initiation of a Phase 2 Clinical Study of ETC-1002 in Patients with Hypercholesterolemia and Hypertension
Jun 11, 2014: Capstone Therapeutics Announces Initiation of Dosing for AEM-28 Phase 1b/2a Human Clinical Trial in Refractory Hypercholesterolemic Subjects
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES


Number of Products under Development for Hypercholesterolemia, H2 2014
Number of Products under Development for Hypercholesterolemia - Comparative Analysis, H2 2014
Number of Products under Development by Companies, H2 2014
Number of Products under Development by Companies, H2 2014 (Contd..1)
Number of Products under Investigation by Universities/Institutes, H2 2014
Comparative Analysis by Late Stage Development, H2 2014
Comparative Analysis by Clinical Stage Development, H2 2014
Comparative Analysis by Early Stage Development, H2 2014
Products under Development by Companies, H2 2014
Products under Development by Companies, H2 2014 (Contd..1)
Products under Investigation by Universities/Institutes, H2 2014
Hypercholesterolemia - Pipeline by Bristol-Myers Squibb Company, H2 2014
Hypercholesterolemia - Pipeline by Johnson & Johnson, H2 2014
Hypercholesterolemia - Pipeline by Amgen Inc., H2 2014
Hypercholesterolemia - Pipeline by Eli Lilly and Company, H2 2014
Hypercholesterolemia - Pipeline by Merck & Co., Inc., H2 2014
Hypercholesterolemia - Pipeline by Pfizer Inc., H2 2014
Hypercholesterolemia - Pipeline by Santaris Pharma A/S, H2 2014
Hypercholesterolemia - Pipeline by SoluBest Ltd., H2 2014
Hypercholesterolemia - Pipeline by Alnylam Pharmaceuticals, Inc., H2 2014
Hypercholesterolemia - Pipeline by Regeneron Pharmaceuticals, Inc., H2 2014
Hypercholesterolemia - Pipeline by CrystalGenomics, Inc., H2 2014
Hypercholesterolemia - Pipeline by Catabasis Pharmaceuticals, Inc., H2 2014
Hypercholesterolemia - Pipeline by Planet Biotechnology Inc., H2 2014
Hypercholesterolemia - Pipeline by Zhejiang Hisun Pharmaceutical Co., Ltd., H2 2014
Hypercholesterolemia - Pipeline by Esperion Therapeutics, Inc., H2 2014
Hypercholesterolemia - Pipeline by Progenra, Inc., H2 2014
Hypercholesterolemia - Pipeline by Serometrix, LLC, H2 2014
Hypercholesterolemia - Pipeline by Hanmi Pharmaceuticals, Co. Ltd., H2 2014
Hypercholesterolemia - Pipeline by AtheroNova Inc., H2 2014
Hypercholesterolemia - Pipeline by Immune Response BioPharma, Inc., H2 2014
Hypercholesterolemia - Pipeline by Agilvax, Inc., H2 2014
Hypercholesterolemia - Pipeline by Michigan Life Therapeutics, LLC, H2 2014
Hypercholesterolemia - Pipeline by LondonPharma Ltd, H2 2014
Hypercholesterolemia - Pipeline by Dybly AG, H2 2014
Assessment by Monotherapy Products, H2 2014
Assessment by Combination Products, H2 2014
Number of Products by Stage and Target, H2 2014
Number of Products by Stage and Mechanism of Action, H2 2014
Number of Products by Stage and Route of Administration, H2 2014
Number of Products by Stage and Molecule Type, H2 2014
Hypercholesterolemia Therapeutics - Recent Pipeline Updates, H2 2014
Hypercholesterolemia - Dormant Projects, H2 2014
Hypercholesterolemia - Discontinued Products, H2 2014

LIST OF FIGURES


Number of Products under Development for Hypercholesterolemia, H2 2014
Number of Products under Development for Hypercholesterolemia - Comparative Analysis, H2 2014
Number of Products under Development by Companies, H2 2014
Number of Products under Investigation by Universities/Institutes, H2 2014
Comparative Analysis by Late Stage Products, H2 2014
Comparative Analysis by Clinical Stage Development, H2 2014
Comparative Analysis by Early Stage Products, H2 2014
Assessment by Monotherapy Products, H2 2014
Number of Products by Top 10 Target, H2 2014
Number of Products by Stage and Top 10 Target, H2 2014
Number of Products by Top 10 Mechanism of Action, H2 2014
Number of Products by Stage and Top 10 Mechanism of Action, H2 2014
Number of Products by Top 10 Route of Administration, H2 2014
Number of Products by Stage and Top 10 Route of Administration, H2 2014
Number of Products by Top 10 Molecule Type, H2 2014
Number of Products by Stage and Top 10 Molecule Type, H2 2014

Ask Your Question

Hypercholesterolemia - Pipeline Review, H2 2014
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry: